28.05.2013 - German biosimilar specialist Formycon AG has named Dr. Carsten Brockmeyer as its new Chief Executive Officer and member of its executive board.
Brockmeyer began his industry career in 1991 at Baxter International, where he was responsible for the development and quality control of monoclonal antibodies. In 1998, he switched to HEXAL AG, where he oversaw the development of the first-ever biosimilar for epoetin alpha and for biosimilar filgrastim. A year later he became General Manager of HEXAL Biotech Forschung GmbH, which was absorbed by Sandoz Biopharmaceuticals in 2008. At Sandoz, Brockmeyer started as head of global project management. In recent years, he has advised clients through his own consulting company, Brockmeyer Biopharma. Formycons new CEO is the author of more than 100 scientific publications, and has been credited with a number of patented inventions. His acclaimed work in the field of biopharmaceuticals has been recognised by several scientific awards.